Answers are grounded in this paper and cite their sources.
The transcription factor NF-kappa B has been well recognized as a pivotal regulator of inflammation in rheumatoid arthritis (RA), but recent developments revealed a broad involvement of NF-kappa B in other aspects of RA pathology, including development of T helper 1 responses, activation, abnormal apoptosis and proliferation of RA fibroblast-like synovial cells, and differentiation and activation of bone resorbing activity of osteoclasts. In agreement with this, studies in animal models of RA have demonstrated the high therapeutic efficacy of specific inhibitors of NF-kappa B pathway, indicating the feasibility of anti-NF-kappa B therapy for human disease.
No takes yet. Share an insight, caveat, or question.
Sergei S. Makarov (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: